BCMA
BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma.
B-cell maturation antigen is nearly universal on myeloma cells. Targeted by CAR-T (ciltacabtagene, idecabtagene), bispecifics (teclistamab, elranatamab, linvoseltamab), and the ADC belantamab mafodotin (re-approved 2025 with DREAMM-7/8).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma.
- 1 · What it is
BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma.
- 2 · What goes wrong in cancer
BCMA is a TNF receptor family member with APRIL and BAFF as ligands. Soluble BCMA can act as a decoy.
- 3 · How drugs use it
7 products aim at BCMA: antibody-drug conjugates, bispecific antibodies and cell therapies. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Biology
BCMA is a TNF receptor family member with APRIL and BAFF as ligands. Soluble BCMA can act as a decoy.
- Multiple myeloma
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Multiple myeloma | >95% | Plasma-cell surface expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Anitocabtagene autoleucel is a BCMA CAR-T with a novel small synthetic binder that produced responses in 97% of heavily pretreated patients; an FDA decision is due in December 2026.
A myeloma ADC that was withdrawn in 2022 then came back in 2025 after strong trials in earlier lines.
Ciltacabtagene autoleucel is a one-time BCMA CAR-T for myeloma that, in CARTITUDE-4, cut the risk of death by about 45% compared with standard regimens.
Elranatamab is Pfizer's BCMA bispecific, given under the skin every week then every two weeks, for myeloma after four prior lines.
Idecabtagene vicleucel was the first myeloma CAR-T (2021) and is now approved after two prior lines based on KarMMa-3.
Linvoseltamab is Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study.
Teclistamab was the first off-the-shelf bispecific for multiple myeloma, and is now approved after just one prior line of therapy.
CARTITUDE-4 is the first randomised trial to show that a CAR-T improves survival in myeloma, and it moved cilta-cel into second-line use (FDA approval 2024). For patients whose disease returns after first-line lenalidomide, a one-off cell therapy now competes with continuous drug combinations. Capacity, cost and the need for bridging therapy still limit who actually receives it.
KarMMa-3 was the first randomised evidence that CAR-T beats conventional drugs in myeloma and led to ide-cel's approval after two prior lines. It confirmed that earlier use of CAR-T produces deeper and longer remissions than in the end-stage setting. Because responses are shorter than with cilta-cel and OS was not improved, it also sharpened debate about which BCMA CAR-T to use and when.
Elranatamab confirmed that BCMA bispecifics are a class, not a one-off, and its protocol-built dose reduction after response set a precedent for lowering the immunosuppressive burden of T-cell engagers. Patients now have two approved BCMA bispecifics and one against GPRC5D (talquetamab). Choosing between them, and sequencing them with CAR-T, remains guided by availability and toxicity profile rather than head-to-head data.
Teclistamab showed that an off-the-shelf bispecific can approach CAR-T-like response rates in late myeloma, giving patients who cannot wait for or access cell therapy a real option. It also exposed the price: prolonged T-cell engagement causes profound immunosuppression, so infection prophylaxis and immunoglobulin replacement are now routine. Less frequent dosing after response is being adopted to reduce this burden.
CARTITUDE-1 showed that a single CAR-T infusion can put late-stage myeloma into deep, multi-year remission, leading to FDA approval of cilta-cel in 2022 for heavily pretreated disease. It set the efficacy bar for BCMA-directed therapy and motivated moving CAR-T earlier (CARTITUDE-4). Late neurological toxicity and secondary malignancies remain the safety questions.
Latest papers
topQuery for this target: (TITLE:"BCMA" OR ABSTRACT:"BCMA" OR TITLE:"TNFRSF17" OR ABSTRACT:"TNFRSF17") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCMA, not a curated reading list.